YTHDF2 and persistent truncus arteriosus: The mice were injected with AAV9 viral particles carrying YTHDF2 (AAV-YTHDF2) through tail intravenous injection, or control AAV for 3 weeks, and the mice were later subjected to TAC to induce cardiac hypertrophy.